The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
- PMID: 20410185
- PMCID: PMC2895050
- DOI: 10.3324/haematol.2009.016329
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
Abstract
A large series of plasma cell dyscrasias (n=2207) was examined for translocations which deregulate the MAF genes, t(14;20)(q32;q12) and t(14;16)(q32;q23), and their disease behavior was compared to a group characterized by the t(4;14)(p16;q32) where CCND2 is also up-regulated. The t(14;20) showed low prevalence in myeloma (27/1830, 1.5%) and smoldering myeloma (1/148, <1%) with a higher incidence in MGUS (9/193, 5% P=0.005). Strong associations with del(13) (76%), non-hyperdiploidy (83%) and gain of 1q (58%) were seen but no association with an IgA M-protein or absence of bone disease was noted. All three translocations were associated with poor outcome in myeloma, but strikingly all t(14;20) MGUS/smoldering myeloma cases (n=10) had stable, low level disease. In contrast, the 10 t(14;16) and 25 t(4;14) MGUS/smoldering myeloma cases were associated with both evolving and non-evolving disease. None of the associated genetic abnormalities helped to predict for progression from MGUS or smoldering myeloma.
Figures
Similar articles
-
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064. Haematologica. 2009. PMID: 19996118 Free PMC article.
-
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27013181
-
Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.Leukemia. 2004 Nov;18(11):1879-82. doi: 10.1038/sj.leu.2403518. Leukemia. 2004. PMID: 15385925
-
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):662-672. doi: 10.1182/hematology.2021000303. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889381 Free PMC article. Review.
-
Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Int J Lab Hematol. 2016. PMID: 27161311 Review.
Cited by
-
Variability of definition of high-risk multiple myeloma across phase III clinical trials.EJHaem. 2023 Mar 28;4(2):454-458. doi: 10.1002/jha2.675. eCollection 2023 May. EJHaem. 2023. PMID: 37206288 Free PMC article.
-
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.J Proteomics. 2016 Mar 16;136:89-98. doi: 10.1016/j.jprot.2015.12.016. Epub 2016 Jan 13. J Proteomics. 2016. PMID: 26775013 Free PMC article. Clinical Trial.
-
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. Epub 2014 Jul 11. Haematologica. 2014. PMID: 25015938 Free PMC article.
-
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.Blood Cancer J. 2022 May 30;12(5):83. doi: 10.1038/s41408-022-00679-5. Blood Cancer J. 2022. PMID: 35637223 Free PMC article. Review.
-
Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.Ann Hematol. 2022 Jul;101(7):1407-1420. doi: 10.1007/s00277-022-04856-1. Epub 2022 May 18. Ann Hematol. 2022. PMID: 35585246 Free PMC article. Review.
References
-
- Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8. - PubMed
-
- Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75. - PubMed
-
- Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191–9. - PubMed
-
- Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95. - PubMed
-
- Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on inter-phase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194–203. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous